Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
The new sharewise is here Clearer, faster, with a light and a dark view — and everything you already know. Try it now
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Get an introduction to all features of this page

CRISPR Therapeutics AG Stock

Price
Target price
€46.59

€46.59

4.000%
1.79
4.000%
€200.00
 
20:02 / Tradegate WKN: A2AT0Z / Symbol: CRSP / Name: CRISPR / Stock / Mid Cap /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of CRISPR Therapeutics AG in the next few years
Wizard

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock CRISPR Therapeutics AG is only available for our menbers.
Not a member yet? Sign up for free!

Financial data and news for CRISPR

sharewise wants to provide you with the best news and tools for CRISPR, so we directly link to the best financial data sources.

Financials

News

Broker

 

News

Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy?: https://g.foolcdn.com/editorial/images/881042/crispr-therapeutics-logo.png
Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy?

CRISPR Therapeutics (NASDAQ: CRSP) has had a terrible year, with the stock down 11% as of writing, while the S&P 500 is up 7%. However, the biotech has several catalysts on the horizon, and some

TheMotleyFool 
0 30.07.26
3 Stocks With the Most Upside by the End of 2026: https://g.foolcdn.com/editorial/images/880076/thinking-man-at-a-desk-reviewing-paperwork.jpg
3 Stocks With the Most Upside by the End of 2026

Are you hoping for a better performance from your portfolio in the latter half of this year than you achieved during the first half? It may require a slightly different selection of stocks.

Here's a

TheMotleyFool 
0 30.07.26
3 Mid-Cap Growth Stocks With Monstrous Long-Term Upside: https://g.foolcdn.com/editorial/images/880485/an-excited-investor-looking-at-a-chart.jpg
3 Mid-Cap Growth Stocks With Monstrous Long-Term Upside

Investing in stocks with modest valuations can set investors up for some significant returns in the long run. While there is more risk involved in putting money into smaller, less-established

TheMotleyFool 
0 28.07.26
Cathie Wood's Ark Bought $21.3 Million of SpaceX Stock as Shares Fell 45% From Their Record High. Wall Street's Median Price Target Is $243.81, 111.5% Above the Current Close.: https://g.foolcdn.com/editorial/images/879997/cathie-wood.jpg
Cathie Wood's Ark Bought $21.3 Million of SpaceX Stock as Shares Fell 45% From Their Record High. Wall Street's Median Price Target Is $243.81, 111.5% Above the Current Close.

Cathie Wood, CEO of Ark Invest, is known for her aggressive investment style. Ark Innovation ETF is heavily invested in growth stocks, including Tesla, Tempus AI, and CRISPR Therapeutics. Roughly

TheMotleyFool 
0 27.07.26